[Pharmacokinetic and clinical studies on ceftriaxone in the field of obstetrics and gynecology].
Ceftriaxone (CTRX) was studied regarding its penetration into the adnexa uteri and uterine tissues, as well as its utility and safety in the treatment of patients with obstetric and gynecologic infections. The results obtained are summarized below. 1. When 1 g of CTRX was administered by intravenous bolus injection, Cmax in tissues of adnexa uteri and uterus ranged from 42.2 to 80.5 micrograms/g, Tmax ranged from 0.42 to 0.81 hour, and the AUC ranged from 314.9 to 606.9 micrograms.hr/g. Thus, drug penetration into these tissues was good. 2. Clinical efficacy of CTRX was evaluated in 29 obstetric and gynecological patients. The clinical efficacy was good in all cases. 3. Bacteriological effects of CTRX were very good, and 90% of the organisms isolated before treatment were eradicated. 4. Laboratory testing revealed an occurrence of mild eosinophilia in 1 case.
Obata
I
I
Department of Obstetrics and Gynecology, Jikei University School of Medicine.
Koike
K
K
Morimoto
O
O
Hachiya
S
S
Yamato
T
T
Hayashi
S
S
Hayashi
M
M
D000031:Abortion, Septic / Q000188:drug therapy; D000038:Abscess / Q000188:drug therapy; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D001472:Bartholin's Glands; D002443:Ceftriaxone / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004716:Endometritis / Q000188:drug therapy; D005184:Fallopian Tube Diseases / Q000188:drug therapy; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D007744:Obstetric Labor Complications / Q000188:drug therapy; D010049:Ovarian Diseases / Q000188:drug therapy; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy; D011247:Pregnancy
D002443:Ceftriaxone